The stock of Genprex Inc (NASDAQ: GNPX) has increased by 6.58 when compared to last closing price of 0.36.Despite this, the company has seen a gain of 17.33% in its stock price over the last five trading days. prnewswire.com reported 2025-03-04 that AUSTIN, Texas, March 4, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 17-19, 2025 in Milan, Italy. In attendance will be Ryan Confer, President and Chief Executive Officer and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing.
Is It Worth Investing in Genprex Inc (NASDAQ: GNPX) Right Now?
Company’s 36-month beta value is -0.55.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for GNPX is 8.28M, and currently, short sellers hold a 7.65% ratio of that floaft. The average trading volume of GNPX on March 17, 2025 was 934.34K shares.
GNPX’s Market Performance
The stock of Genprex Inc (GNPX) has seen a 17.33% increase in the past week, with a -17.79% drop in the past month, and a -63.12% fall in the past quarter. The volatility ratio for the week is 10.28%, and the volatility levels for the past 30 days are at 10.98% for GNPX. The simple moving average for the last 20 days is 5.79% for GNPX’s stock, with a simple moving average of -65.95% for the last 200 days.
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at -27.84% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.36% of loss for the given period.
Volatility was left at 10.98%, however, over the last 30 days, the volatility rate increased by 10.28%, as shares sank -12.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.56% lower at present.
During the last 5 trading sessions, GNPX rose by +17.27%, which changed the moving average for the period of 200-days by -81.75% in comparison to the 20-day moving average, which settled at $0.3660. In addition, Genprex Inc saw -54.53% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GNPX
Current profitability levels for the company are sitting at:
- -985.8 for the present operating margin
- 0.64 for the gross margin
The net margin for Genprex Inc stands at -980.82. The total capital return value is set at -13.71. Equity return is now at value -325.11, with -221.01 for asset returns.
Currently, EBITDA for the company is -31.06 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 79.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
In a nutshell, Genprex Inc (GNPX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
